- Home
- IMA vs LUCD Comparison
IMA vs LUCD Comparison
Compare IMA & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMA
- LUCD
- Stock Information
- Founded
- IMA 2019
- LUCD 2018
- Country
- IMA United States
- LUCD United States
- Employees
- IMA N/A
- LUCD N/A
- Industry
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IMA Health Care
- LUCD Health Care
- Exchange
- IMA Nasdaq
- LUCD Nasdaq
- Market Cap
- IMA 92.2M
- LUCD 108.0M
- IPO Year
- IMA N/A
- LUCD 2021
- Fundamental
- Price
- IMA $8.11
- LUCD $1.28
- Analyst Decision
- IMA Buy
- LUCD Strong Buy
- Analyst Count
- IMA 1
- LUCD 5
- Target Price
- IMA $30.00
- LUCD $3.70
- AVG Volume (30 Days)
- IMA 91.8K
- LUCD 1.3M
- Earning Date
- IMA 11-15-2025
- LUCD 11-12-2025
- Dividend Yield
- IMA N/A
- LUCD N/A
- EPS Growth
- IMA N/A
- LUCD N/A
- EPS
- IMA N/A
- LUCD N/A
- Revenue
- IMA $4,300,000.00
- LUCD $4,360,000.00
- Revenue This Year
- IMA N/A
- LUCD $13.90
- Revenue Next Year
- IMA N/A
- LUCD $154.24
- P/E Ratio
- IMA N/A
- LUCD N/A
- Revenue Growth
- IMA N/A
- LUCD 14.74
- 52 Week Low
- IMA $7.24
- LUCD $0.75
- 52 Week High
- IMA $23.28
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- IMA N/A
- LUCD 61.73
- Support Level
- IMA N/A
- LUCD $1.17
- Resistance Level
- IMA N/A
- LUCD $1.27
- Average True Range (ATR)
- IMA 0.00
- LUCD 0.08
- MACD
- IMA 0.00
- LUCD 0.01
- Stochastic Oscillator
- IMA 0.00
- LUCD 94.34
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.